"Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C (TRIUMPH-2, TRIUMPH-3)." Investor Relations
1 (As detailed in the safety section, BPC-157 was placed on the FDAs Category 2 compounding list in 2023 and then removed from it in April 2026 on procedural grounds a change that does not amount to approval and leaves the compound unapproved and investigational.) Evidence grade: promising in animals, unproven in humans
EMPA-KIDNEY, Study of Heart and Kidney Protection with Empagliflozin
Unlock the Potential of GHK-Cu 100mg for Skin Regeneration and Tissue Repair Research Discover GHK-Cu 100mg from ReVICO Labs a high-purity, lyophilized copper-histidine peptide complex designed for controlled laboratory investigation into skin health, collagen synthesis, and extracellular matrix remodeling